Eric M. Morrel
Fondateur chez Benu BioPharma, Inc.
Profil
Eric M.
Morrel is the founder of Benu BioPharma, Inc. He is currently the Director & Vice President at LipimetiX Development LLC.
Previously, he held positions such as Associate Director-Clinical Operations at Transkaryotic Therapies, Inc., Assistant Director-Medical Affairs at BioMarin Pediatrics II, Inc., Vice President-Clinical Research at Transport Pharmaceuticals, Inc., and Vice President-Clinical Research at eXIthera Pharmaceuticals, Inc. Morrel received his graduate and doctorate degrees from Massachusetts Institute of Technology and his undergraduate degree from Princeton University.
Postes actifs de Eric M. Morrel
| Sociétés | Poste | Début |
|---|---|---|
Benu BioPharma, Inc.
 Benu BioPharma, Inc. Miscellaneous Commercial ServicesCommercial Services Benu BioPharma, Inc. operates a biopharmaceutical development management and consulting company. Its services include development, consulting, product specific services and portfolio triage. The company is headquartered in Natick, MA. | Fondateur | - |
LipimetiX Development LLC
 LipimetiX Development LLC Pharmaceuticals: MajorHealth Technology LipimetiX Development LLC operates as a biopharmaceutical company. It develops drugs for the treatment of refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company is headquartered in Natick, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Eric M. Morrel
| Sociétés | Poste | Fin |
|---|---|---|
eXIthera Pharmaceuticals, Inc.
 eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | Directeur Technique/Scientifique/R&D | - |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Directeur des opérations | - |
BioMarin Pediatrics II, Inc.
 BioMarin Pediatrics II, Inc. Pharmaceuticals: OtherHealth Technology BioMarin Pediatrics II, Inc. engages in the manufacture, development and sale of pharmaceutical products or children. The company was founded by Emmett Clemente in 1989 and is headquartered in DE. | Corporate Officer/Principal | - |
Transport Pharmaceuticals, Inc.
 Transport Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Transport Pharmaceuticals, Inc. engaged in the development of medical products for the treatment of multiple dermatological diseases. It developed iontophoretic technique to effect trans-dermal drug delivery for a number of dermatological conditions. The company was founded by Dennis I. Goldberg in 1999 and was headquartered in Framingham, MA. | Corporate Officer/Principal | - |
Formation de Eric M. Morrel
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
BioMarin Pediatrics II, Inc.
BioMarin Pediatrics II, Inc. Pharmaceuticals: OtherHealth Technology BioMarin Pediatrics II, Inc. engages in the manufacture, development and sale of pharmaceutical products or children. The company was founded by Emmett Clemente in 1989 and is headquartered in DE. | Health Technology |
Transport Pharmaceuticals, Inc.
Transport Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Transport Pharmaceuticals, Inc. engaged in the development of medical products for the treatment of multiple dermatological diseases. It developed iontophoretic technique to effect trans-dermal drug delivery for a number of dermatological conditions. The company was founded by Dennis I. Goldberg in 1999 and was headquartered in Framingham, MA. | Health Technology |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | Health Technology |
Benu BioPharma, Inc.
Benu BioPharma, Inc. Miscellaneous Commercial ServicesCommercial Services Benu BioPharma, Inc. operates a biopharmaceutical development management and consulting company. Its services include development, consulting, product specific services and portfolio triage. The company is headquartered in Natick, MA. | Commercial Services |
LipimetiX Development LLC
LipimetiX Development LLC Pharmaceuticals: MajorHealth Technology LipimetiX Development LLC operates as a biopharmaceutical company. It develops drugs for the treatment of refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company is headquartered in Natick, MA. | Health Technology |
